The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

Isis Pharmaceuticals, Inc. [ISIS] to Ring The NASDAQ Stock Market Closing Bell

Thursday, February 14, 2013

Isis Pharmaceuticals, Inc. [ISIS] to Ring The NASDAQ Stock Market Closing Bell07:00 EST Thursday, February 14, 2013 ADVISORY, Feb. 14, 2013 (GLOBE NEWSWIRE) --What: Isis Pharmaceuticals, Inc. [ISIS], the leading company in antisense drug discovery and development, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Lynne Parshall, Chief Operating Officer, will ring the Closing Bell.Where: NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen: Friday, February 15, 2013 – 3:45 p.m. to 4:00 p.m. ET  Contacts:Amy Blackley (760) 603-2772 ablackley@isisph.com Wade Walke (760) 603-2741 wwalke@isiph.comNASDAQ MarketSite:Jen Knapp (212) 401-8916 Jennifer.knapp@nasdaqomx.comFeed Information:Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSKFacebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.         For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.Webcast:A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.About Isis Pharmaceuticals, Inc. [ISIS]: Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.About NASDAQ OMX Group: The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 23 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (www.facebook.com/NASDAQ) and Twitter (www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500) -NDAQA-